Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
neurodegenerative disease
|
| gptkbp:affects |
central nervous system
substantia nigra |
| gptkbp:alsoKnownAs |
gptkb:Parkinson's_disease
PD |
| gptkbp:causedBy |
loss of dopamine-producing neurons
|
| gptkbp:characterizedBy |
bradykinesia
postural instability rigidity tremor |
| gptkbp:complication |
gptkb:dementia
gptkb:pneumonia falls swallowing difficulties |
| gptkbp:diagnosedBy |
response to levodopa
clinical examination neurological assessment |
| gptkbp:firstDescribed |
gptkb:James_Parkinson
1817 |
| gptkbp:hasNoCure |
true
|
| https://www.w3.org/2000/01/rdf-schema#label |
Parkinson Disease
|
| gptkbp:ICD-10_code |
gptkb:G20
|
| gptkbp:MeSH_ID |
D010300
|
| gptkbp:OMIM |
168600
|
| gptkbp:prevalence |
affects about 1% of people over 60
more common in people over 60 more common in men |
| gptkbp:progression |
progressive
chronic |
| gptkbp:researchInterest |
genetics
stem cell therapy environmental factors neuroprotection |
| gptkbp:riskFactor |
age
family history exposure to pesticides |
| gptkbp:symptom |
gptkb:depression
balance problems muscle stiffness resting tremor shuffling gait sleep disturbances slowness of movement speech changes writing changes |
| gptkbp:treatment |
gptkb:levodopa
occupational therapy physical therapy speech therapy MAO-B inhibitors deep brain stimulation dopamine agonists |
| gptkbp:bfsParent |
gptkb:D010141
|
| gptkbp:bfsLayer |
7
|